Expertise in
2
conditions

Dr. Lemuel S. Ariaratnam

Radiation Oncology
Virtua Mount Holly Hospital
175 Madison Ave, 
Mount Holly, NJ 
Expertise in
2
conditions
Virtua Mount Holly Hospital
175 Madison Ave, 
Mount Holly, NJ 

Overview

Lemuel Ariaratnam is a Radiation Oncologist practicing medicine in Mount Holly, New Jersey.

Dr. Ariaratnam is highly rated in 2 conditions, according to our data. His clinical expertise encompasses Breast Cancer, Pleuropulmonary Blastoma, Tongue Cancer, and Prostate Cancer.

He is actively involved in clinical research, participating in 17 clinical trials.

Specialties

Radiation Oncology

Licenses

Radiology in NJ

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO

Locations

Virtua Mount Holly Hospital
175 Madison Ave, Mount Holly, NJ 08060

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

17 Clinical Trials

Randomized Phase II Trial of Hypofractionated Dose-Escalated Photon IMRT or Proton Beam Therapy Versus Conventional Photon Irradiation With Concomitant and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma
Randomized Phase II Trial of Hypofractionated Dose-Escalated Photon IMRT or Proton Beam Therapy Versus Conventional Photon Irradiation With Concomitant and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Radiation, Drug
Study Drug: Temozolomide
Study Phase: Phase 2
A Phase II, Double-Blinded, Placebo-Controlled Randomized Trial of Salvage Radiotherapy With or Without Enhanced Anti-Androgen Therapy With Apalutamide in Recurrent Prostate Cancer (BALANCE*)
A Phase II, Double-Blinded, Placebo-Controlled Randomized Trial of Salvage Radiotherapy With or Without Enhanced Anti-Androgen Therapy With Apalutamide in Recurrent Prostate Cancer (BALANCE*)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Radiation, Drug
Study Drug: Apalutamide
Study Phase: Phase 2
A Randomized Phase III Trial of Radiation Therapy and Cisplatin Alone or in Combination With Intravenous Triapine in Women With Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer
A Randomized Phase III Trial of Radiation Therapy and Cisplatin Alone or in Combination With Intravenous Triapine in Women With Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 21, 2026
Intervention Type: Radiation, Drug, Other
Study Drugs: Cisplatin, Triapine
Study Phase: Phase 3
A Phase IIR/III Trial of Standard of Care Therapy With or Without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer
A Phase IIR/III Trial of Standard of Care Therapy With or Without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer
Enrollment Status: Completed
Publish Date: July 10, 2026
Intervention Type: Radiation, Procedure
Study Phase: Phase 2/Phase 3
A Phase 1 Study of Stereotactic Body Radiotherapy (SBRT) for the Treatment of Multiple Metastases
A Phase 1 Study of Stereotactic Body Radiotherapy (SBRT) for the Treatment of Multiple Metastases
Enrollment Status: Completed
Publish Date: June 25, 2026
Intervention Type: Radiation
Study Phase: Phase 1
Maintenance Systemic Therapy Versus Local Consolidative Therapy (LCT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial
Maintenance Systemic Therapy Versus Local Consolidative Therapy (LCT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial
Enrollment Status: Active_not_recruiting
Publish Date: June 08, 2026
Intervention Type: Radiation, Drug
Study Drugs: Docetaxel, Gemcitabine, Pemetrexed Disodium, Erlotinib Hydrochloride, Pembrolizumab
Study Phase: Phase 2
A Randomized Phase II Trial for Patients With p16 Positive, Non-Smoking Associated, Locoregionally Advanced Oropharyngeal Cancer
A Randomized Phase II Trial for Patients With p16 Positive, Non-Smoking Associated, Locoregionally Advanced Oropharyngeal Cancer
Enrollment Status: Completed
Publish Date: May 22, 2026
Intervention Type: Drug, Radiation
Study Drug: Cisplatin
Study Phase: Phase 2
Randomized Phase II Trial of Postoperative Adjuvant IMRT Following Cystectomy for pT3/T4 Urothelial Bladder Cancer
Randomized Phase II Trial of Postoperative Adjuvant IMRT Following Cystectomy for pT3/T4 Urothelial Bladder Cancer
Enrollment Status: Terminated
Publish Date: May 22, 2026
Intervention Type: Radiation
Study Phase: Phase 2
Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial
Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial
Enrollment Status: Active_not_recruiting
Publish Date: May 08, 2026
Intervention Type: Radiation, Drug
Study Phase: Phase 3
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: May 06, 2026
Intervention Type: Drug, Other
Study Drugs: Carboplatin, Cyclophosphamide, Doxorubicin Hydrochloride, Paclitaxel
Study Phase: Phase 3
View 9 Less Clinical Trials
Similar Doctors
Expertise in
38
conditions
Dr. Keith A. Cengel
Radiation Oncology
Expertise in
38
conditions
Dr. Keith A. Cengel
Radiation Oncology
Referral may be required
Before you request

Penn Radiation Oncology Perelman - 2nd Floor

3400 Civic Center Boulevard, West Pavilion, 2nd Floor, 
Philadelphia, PA 
 (21.2 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Keith Cengel is a Radiation Oncologist practicing medicine in Philadelphia, Pennsylvania. Dr. Cengel is highly rated in 38 conditions, according to our data. His clinical expertise encompasses Mesothelioma, Lung Cancer, Metastatic Pleural Tumor, Small Cell Lung Cancer (SCLC), and Liver Embolization. Dr. Cengel is board certified in Radiation Oncology, 2008. Dr. Cengel is currently accepting new patients.

Expertise in
34
conditions
Dr. Wenyin J. Shi
Radiation Oncology
Expertise in
34
conditions
Dr. Wenyin J. Shi
Radiation Oncology
Referral may be required

Radiation Oncology At Thomas Jefferson University Hospital

111 South 11th Street, Suite G-301, 
Philadelphia, PA 
 (19.4 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Wenyin Shi is a Radiation Oncologist practicing medicine in Philadelphia, Pennsylvania. Dr. Shi is highly rated in 34 conditions, according to our data. His clinical expertise encompasses Astrocytoma, Mycosis Fungoides, Glioblastoma, Brain Tumor, and Gamma Knife Radiosurgery. Dr. Shi is board certified in Radiation Oncology and Radiology. Dr. Shi is currently accepting new patients.

Expertise in
27
conditions
Dr. Jeffrey D. Bradley
Radiation Oncology
Expertise in
27
conditions
Dr. Jeffrey D. Bradley
Radiation Oncology
Referral may be required
Before you request

Penn Radiation Oncology Perelman-Concourse Level

3400 Civic Center Boulevard, Concourse Level, 
Philadelphia, PA 
 (21.2 miles away)
800-789-7366
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Jeffrey Bradley is a Radiation Oncologist practicing medicine in Philadelphia, Pennsylvania. Dr. Bradley is highly rated in 27 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), and Thymic Epithelial Tumor. Dr. Bradley is board certified in Radiation Oncology, 1998. Dr. Bradley is currently accepting new patients.

Frequently Asked Questions about Dr. Lemuel S. Ariaratnam

How do I make an appointment with Dr. Lemuel S. Ariaratnam?

You can book an appointment with Dr. Lemuel S. Ariaratnam by calling their office at 609-914-7074. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Lemuel S. Ariaratnam a top-rated expert for Breast Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Lemuel S. Ariaratnam is classified as an Advanced expert for Breast Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Lemuel S. Ariaratnam specialize in?

While Dr. Lemuel S. Ariaratnam is a Radiation Oncology, they have specific expertise in Breast Cancer, Pleuropulmonary Blastoma, and Tongue Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Radiation Oncology.

Does Dr. Lemuel S. Ariaratnam accept my insurance?

Dr. Lemuel S. Ariaratnam accepts most major insurance plans, including Humana. We recommend calling the office directly at 609-914-7074 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Ariaratnam's expertise for a condition
ConditionClose
      View All 15 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile